Here’s whether Bristol-Myers Squibb Co. (BMY) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+3.12% over 10 days); RSI 55 — healthy momentum range; strong 1-year return of +38.4%; 3-month momentum positive (+12.7%). Concerns: declining volume on rally — weak conviction (0.78x 30d avg). Currently 2.4% off its 52-week high. Score: +6/7.
BMY is in a confirmed uptrend, trading above both its 50-day ($60.57) and 200-day ($57.14) moving averages. An RSI of 55.3 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +38.4% compares to +20.5% for SPY (beat the market by 17.9%).
$10,000 invested 1 year ago→ $13,836 today
vs. S&P 500 (SPY) — same period beat market by 17.9%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($57.14)
✓Above 50-day MA ($60.57)
✓RSI(14) neutral zone (30–70) — currently 55.3
✓Positive return (+38.4%)
✓Within 10% of period high (−2.4%)
Period Range $67.01
$42.52$68.64
RSI (14) 55.3
0 · OversoldOverbought · 100
Key Metrics
Price$67.01
Period Return+38.4%
Period High$68.64
Period Low$42.52
Drawdown−2.4%
MA-50$60.57
MA-200$57.14
RSI (14)55.3
Avg Volume (30d)11.8M
vs. SPYbeat by 17.9%
Return Rank#301 of 999
Trend Signals
Price is above the 200-day moving average ($57.14)